We are looking forward to the 7th AMR Conference, March 16-17, Basel, Switzerland, where our CEO, Lloyd Payne and founder Zemer Gitai will be attending.

ArrePath is looking forward to taking part in BioInfect 2023 on February 1, 2023

ArrePath today announced that it has appointed two new members to its Scientific Advisory Board (SAB):  Connor Coley, PhD, Henri Slezynger (1957) Career Development Assistant Professor in Chemical Engineering at MIT, and Paul Hergenrother, PhD, Kenneth L. Rinehart Jr. Endowed Chair in Natural Products Chemistry, and Professor of Chemistry at the University of Illinois Urbana-Champaign.

ArrePath is presenting at MassBio Innovation Week, December 6, 2022

ArrePath will be attending the seventh annual CytoData meeting, hosted by the Allen Institute for Cell Science, which will take place October 17-20, 2022 in Seattle, Washington.

ArrePath is attending the World Anti-Microbial Resistance Congress taking place on September 7-8, 2022, in National Harbor, MD.

Join ArrePath at 2022 NeurIPS, a premier conference on Machine Learning and AI. This event is taking place at the New Orleans Convention Center on Monday, November 28th – Friday, December 9th.

ArrePath today announced the appointment of Michael Dudley, PharmD, as Chairman of the Company’s Board of Directors.

ArrePath announced today that it has raised $20 million in seed financing to advance its proprietary, machine learning (ML)-based platform for the discovery of new classes of anti-infectives to overcome antimicrobial resistance (AMR).

ArrePath will be at the 2022 Gordon Research Conference on New Antibacterial Discovery and Development happening July 24 – 29, 2022.